Publication | Closed Access

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

Metabolic SyndromeDiabetes ManagementCanagliflozin Versus GlimepirideHealth SciencesInsulin ManagementDiabetesType 2Clinical TrialsDiabetes MellitusMedicineWeek Results